Is the En Bloc Transurethral Resection More Effective than Conventional Transurethral Resection for Non-Muscle-Invasive Bladder Cancer? A Systematic Review and Meta-Analysis
Authors:
- 7 January 2020
- journal article
- review article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 104 (5-6) , 402-409
Abstract
Background: En bloc transurethral resection (ERBT) is a major topic of discussion as an alternative to conventional transurethral resection (cTURBT) for the treatment of non-muscle-invasive bladder cancer (NMIBC) addressing the limitations of cTURBT. Methods: We searched through electronic databases including Embase, Cochrane Library, MEDLINE, Web of Science, PubMed, and Google Scholar for articles published up to April 1, 2019; RevMan 5.3 was used to conduct this meta-analysis. Results were expressed as 95% confidence intervals (CI) and risk differences (RD). Results: Nine trials met the inclusion criteria (n = 1,020 patients): 1 study was a randomized controlled trial including a total of 142 participants, 4 studies had a prospective paired design including 605 patients, and 4 studies were retrospective (n = 273 patients). Duration of continuous postoperative bladder irrigation (RD –0.16; 95% CI –3.47 to 0.28; I2 = 97%; p = 0.10) and operation time (RD 0.05; 95% CI –0.23 to 0.32; I2 = 79%; p = 0.74) were not significantly different between ERBT and cTURBT. However, hospitalization time (I2 = 96%; χ2 = 203.16; p = 0.01) and catheterization time (I2 = 95%; χ2 = 163.24; p = 0.02), as well as 24-month recurrence rate (I2 = 0%; χ2 = 0.98; p = 0.008) were significantly better using the ERBT scheme. The incidence of urethral stricture between both schemes (95% CI –0.03 to 0.02; p = 0.50) was not different, but complications such as obturator nerve reflex (95% CI 0.01 to 0.12; p < 0.00001) and bladder perforation (95% CI 0.05 to 0.59; p = 0.50) were less frequent in the ERBT group. Conclusion: ERBT is an effective treatment approach with some advantages for NMIBC. Our meta-analysis revealed that hospitalization time, catheterization time, and 24-month recurrence rate is superior in patients treated with ERBT than cTURBT, and ERBT patients also have a lower complication rate. Furthermore, ERBT improves the quality of tumor specimens and decreases the frequency of repeat transurethral bladder cancer resection. Further randomized controlled trials are needed to confirm our results.Keywords
This publication has 24 references indexed in Scilit:
- Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancerMinimally Invasive Therapy & Allied Technologies, 2014
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013European Urology, 2013
- Current evidence for transurethral laser therapy of non-muscle invasive bladder cancerWorld Journal of Urology, 2011
- Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator ExperienceEuropean Urology, 2010
- Clinical observation on 2 micron laser for non-muscle-invasive bladder tumor treatment: single-center experienceWorld Journal of Urology, 2010
- Comparing the Safety and Efficiency of Conventional Monopolar, Plasmakinetic, and Holmium Laser Transurethral Resection of Primary Non-muscle Invasive Bladder CancerJournal of Endourology, 2010
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- Safety and Efficacy of Holmium Laser Resection for Primary Nonmuscle-Invasive Bladder Cancer Versus Transurethral Electroresection: Single-Center ExperienceUrology, 2008
- SHOULD UROLOGISTS BE SPENDING MORE TIME ON THE GOLF COURSE?BJU International, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003